Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03376659 · ClinicalTrials.gov registry record · Phase 1
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03376659 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 8 participants.
The verdict
NCT03376659, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a dual arm, open label phase I/II study to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancer whose disease is stable on, or responding to 1st line therapy for metastatic disease. Patients with metastatic colorectal or pancreatic adenocarcinoma who still have an adequate performance status and normal hepatic and renal function will be eligible.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Durvalumab
- BIOLOGICAL CV301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2023-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03376659
The ClinicalTrials.gov registry entry for NCT03376659 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03376659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03376659 about?
NCT03376659 is a clinical study titled "Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma". This is a dual arm, open label phase I/II study to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancer whose disease is stable on, or responding to 1st line the...
What is the current status of trial NCT03376659?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-08-08. Estimated completion is 2023-08-01.
What interventions are being tested in trial NCT03376659?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Durvalumab (DRUG), CV301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03376659?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.